KALA BIO, Inc. (NASDAQ:KALA) CFO Mary Reumuth Sells 1,706 Shares

KALA BIO, Inc. (NASDAQ:KALA) CFO Mary Reumuth sold 1,706 shares of the business’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $7.63, for a total transaction of $13,016.78. Following the transaction, the chief financial officer now owns 68,581 shares in the company, valued at $523,273.03. This represents a 2.43 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

KALA BIO Trading Up 2.1 %

Shares of KALA BIO stock opened at $7.69 on Wednesday. The company has a debt-to-equity ratio of 3.18, a current ratio of 2.15 and a quick ratio of 2.15. The business has a fifty day simple moving average of $6.71 and a two-hundred day simple moving average of $6.32. KALA BIO, Inc. has a 1 year low of $4.21 and a 1 year high of $9.25. The company has a market capitalization of $35.45 million, a price-to-earnings ratio of -0.62 and a beta of -2.11.

KALA BIO (NASDAQ:KALA) last posted its earnings results on Tuesday, November 12th. The company reported ($1.93) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.43) by $0.50. Research analysts forecast that KALA BIO, Inc. will post -10.84 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of KALA BIO in a research report on Friday, November 15th.

Institutional Investors Weigh In On KALA BIO

A hedge fund recently bought a new stake in KALA BIO stock. SR One Capital Management LP purchased a new position in shares of KALA BIO, Inc. (NASDAQ:KALA) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO comprises about 1.0% of SR One Capital Management LP’s investment portfolio, making the stock its 9th largest holding. SR One Capital Management LP owned approximately 15.76% of KALA BIO as of its most recent filing with the SEC. 24.61% of the stock is currently owned by institutional investors and hedge funds.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.